The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 574-580 , September 2008

Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

  • Mariana C. Castells, MD, PhD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationReprint requests: Mariana C. Castells, MD, PhD, One Jimmy Fund Way, Smith Building, Room 626D, Boston, MA 02115.
    • These authors contributed equally to this work.
    • ,
  • Nichole M. Tennant, BA

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • David E. Sloane, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • F. Ida Hsu, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • Nora A. Barrett, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • David I. Hong, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Tanya M. Laidlaw, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Henry J. Legere, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Samridhi N. Nallamshetty, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Ross I. Palis, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Jayanti J. Rao, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Suzanne T. Berlin, DO

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass
    • ,
  • Susana M. Campos, MD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass
    • ,
  • Ursula A. Matulonis, MD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass

Received 14 December 2007 ,Revised 27 February 2008 ,Accepted 29 February 2008.

References 

  1. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141–1145
  2. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84:378–382
  3. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53:121–122
  4. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001;19:3126–3129
  5. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecological oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102–105
  6. Goldberg A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol. 1996;98:841–843
  7. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94:575–580
  8. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824–829
  9. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95:370–376
  10. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99:393–399
  11. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol. 2003;14:497–498
  12. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;21:4611–4614
  13. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–1268
  14. Balsari A, Lombardo N, Ghione M. Skin and perivascular toxicity induced experimentally by doxorubicin. J Chemother. 1989;1:324–329
  15. Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol. 2004;93:137–141
  16. Castells M. Drug desensitization in oncology: chemotherapy agents and moncolonal antibodies. In:  Pichler WJ editors. Drug hypersensitivity. New York: Karger; 2007;p. 413–425
  17. Sheffer AL, Feldweg AM, Castells M. Anaphylaxis. In:  Holgate ST,  Church MK,  Lichtenstein LM editor. Allergy. London: Mosby Elsevier; 2006;p. 167–178
  18. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol. 1999;162:6811–6818
  19. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol. 2001;166:574–581
  20. Sykes E, Woodburn K, Decker D, Kessel D. Effects of Cremophor EL on distribution of taxol to serum lipoproteins. Br J Cancer. 1994;70:401–404
  21. Wendel GD, Stark BJ, Jamison RB, Molina RB, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312:1229–1232
  22. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer 2006;354:34-43.
  23. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007;109:4171–4173
  24. Rosique-Robles D, Vicent Verge JM, Borras-Blasco J, Giner-Marco V, Castera E, Galan-Brotons A, et al. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin. Int J Clin Pharmacol Ther. 2007;45:606–610

 Supported by the Ovations for the Cure Desensitization Program.

 Disclosure of potential conflict of interest: D. E. Sloane has received honoraria from Genentech. F. I. Hsu has served as a coinvestigator for Dyax Corporation and has received a research grant from the American Academy of Allergy, Asthma & Immunology. N. A. Barrett has served as a coinvestigator for the National Institutes of Health and has served as a primary investigator for the American Academy of Allergy, Asthma & Immunology and Altana. D. I. Hong and T. M. Laidlaw have received training grant salary from the National Institutes of Health. S. N. Nallamshetty has received training grant salary from the National Institutes of Health and research grants from the American Academy of Allergy, Asthma & Immunology and GlaxoSmithKline. S. M. Campos has served as a research consultant for Genentech and has received research support from Genentech, Novartis, and Ortho-Biotechnology. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00762-8

doi: 10.1016/j.jaci.2008.02.044

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 574-580 , September 2008

Article Tools

* Image Usage & Resolution